A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients.

By P. Pappas, J. Rex, Jeannette Y. Lee, R. Hamill, R. Larsen, W. Powderly, C. Kauffman, N. Hyslop, J. Mangino, S. Chapman and 3 more. Clinical Infectious Diseases, 2003

838 citations recorded by the source corpus.

Subfields: Epidemiology, Infectious Diseases, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/3fbe4223a042e409da149b84310a01c4b55344e7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. M. Pfaller
2. D. Diekema
3. J. Guinea
4. M. Nucci
5. T. Walsh
6. Thierry Calandra
7. E. Anaissie

In Infectious Diseases

1. M. Pfaller
2. D. Diekema
3. J. Guinea
4. M. Nucci
5. J. Fishman
6. E. Anaissie

Citations in the corpus

• Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. (2009, background): “albicans Candida species, in both pediatric and adult patient populations [8, 29, 30].”
• Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. (2007, background): “This has been a shortcoming among all randomized therapeutic studies of invasive candidiasis [19,20,24,27], reflecting the difficulty of enrolling such patients in clinical trials [3].”
• Global trends in the distribution of Candida species causing candidemia. (2014, background): “Candidemia has an attributable mortality of 15–35% for adults and 10–15% for neonates, and the hospitalization cost for each episode is approximately US$40 000 [11–13].”
• Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America (2009, background): “The most frequently implicated risk factors include the use of broad-spectrum antibacterial agents, use of central venous catheters, receipt of parenteral nutrition, receipt of renal replacement therapy by patients in ICUs, neutropenia, use of implantable prosthetic devices, and receipt of immunosup”
• Strains and Strategies for Large-Scale Gene Deletion Studies of the Diploid Human Fungal Pathogen Candida albicans (2005, background): “is between $1 and $2 billion annually (34, 51), and despite aggressive therapies, mortality approaches 50% (49, 18, 32, 3).”
• Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem (2007, background): “attributable mortality (21, 22, 188), then treatment may not be”
• Real-Time PCR in Clinical Microbiology: Applications for Routine Laboratory Testing (2006, background): “Candida species are the fourth leading cause of nosocomial bloodstream infections and are associated with a mortality rate of 40 to 50% so rapid and reliable detection of candidemia has attracted significant interest (105, 152, 366).”
• Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. (2016, background): “world for more than a decade [5–12].”